Menu

Prevalent Form of Childhood Leukemia May Be Preventable

Early exposure to common microbes could stop leukemia from manifesting in children.

May 22, 2018
Sukanya Charuchandra

ISTOCK, FATCAMERAAn analysis of more than 30 years of research has revealed the underlying cause of the most common form of leukemia in children. Research compiled in Nature Reviews Cancer on May 21 suggests that acute lymphoblastic leukemia (ALL) occurs by a two-step process—first, a mutation occurs in the fetus and a second mutation, later in life and triggered by infection, spurs the cancer to develop.

“The most important implication is that most cases of childhood leukemia are likely to be preventable,” Melvyn Greaves, a cancer biologist at the Institute of Cancer Research in the U.K. and the author of the paper, says in a statement.

Only 1 percent of children born with an ALL-related mutation go on to have the disease. The ones who do have had little experience with common infections such as the flu in their formative years, according to Greaves. This lack of immune priming predisposes them to a genetic change caused by a later infection and, ultimately, causes the disease, Greaves proposes in his paper.

See “Researchers Publish First Pan-Cancer Genomic Analyses in Pediatric Patients

Greaves collated research from the fields of genetics, cell biology, immunology, and epidemiology. Further, experiments in mice support his conclusions. Mice with leukemia-initiating mutations born into a sterile environment developed ALL only when they were transferred to unclean surroundings.

“This research sheds light on how a form of childhood blood cancer might develop, implicating a complex combination of genetics and early exposure to germs, dirt and illness,” Charles Swanton, Cancer Research UK’s chief clinician, tells The Independent.

See “Cancer Evolutionist: A Profile of Charles Swanton

While 90 percent of children with ALL are cured by chemotherapy, it can leave lasting effects. ALL cases are growing by 1 percent every year, mostly in richer nations, according to Greaves, who tells The Guardian, “The problem is lack of infection.” He says social contact might expose young children born with mutations that predispose them to ALL to harmless infections that may prevent leukemia at a later stage. He is now testing this theory of early exposure to common bacteria and viruses in mutant mice.

Donna Lancaster, a pediatric oncologist in the National Health Service in the U.K., tells New Scientist this “needs further investigation and any exposure of young children to infection has to be balanced with the risk of the infection.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.